A New Hope for Dry AMD

First and only Dry AMD Treatment – Now available

• FDA-approved light therapy
• Stimulates retinal cells
• Non-invasive and painless

Valeda uses multiple wavelengths of light to activate cellular regeneration in the retina.

What is Valeda?

Valeda uses specific wavelengths of light (590, 660, and 850 nm) to stimulate cellular repair, reduce inflammation, and enhance mitochondrial function. This innovative therapy targets the root causes of dry AMD, such as oxidative damage and cellular dysfunction, to preserve vision and improve eye health. Stated another way, it puts more energy into the regnerative cell repair while decreasing the harmful effects of immaflamation which can hasten cell death. Remember, 85-90% of macular degeneration is Dry AMD.  If you act now, you may be able to preserve or even improve you sight.

How Valeda Works

Valeda delivers light therapy in four phases during each session:

• Phase 1: 590 and 850 nm pulsed light (35 seconds, eyes open).
• Phase 2: 660 nm continuous light (90 seconds, eyes closed).
• Phase 3: 590 and 850 nm pulsed light (35 seconds, eyes open).
• Phase 4: 660 nm continuous light (90 seconds, eyes closed).

Each session lasts approximately 4 minutes and 10 seconds and is completely non-invasive. 

Treatment Process

A Treatment Series: Nine (9) sessions delivered 3 times per week over 3–5 weeks.

Frequency: Treatment series are repeated every 4 months.

No Pupil Dilation Required: Sessions are straightforward and require minimal preparation.

Clinical Benefits

Improved Visual Acuity:

Gain in visual acuity was documented in the average patient and lasted over two years (end of study measuments)

In this study, patients who had more significant visual impairment in the beginning experienced greater improvement compared to those who had better visual acuity initially.

Reduction in Disease Progression:

Slows the development of geographic atrophy (GA) and reduces macular drusen volume.

Enhanced Quality of Life:

Better near vision and improved ability to perform daily activities like reading.

Safety Profile

• Non-Invasive: Valeda uses LED light, not lasers, ensuring no thermal treatment or local cellular damage.
• No Serious Adverse Events: Clinical trials report no phototoxicity (damage to light-sensitive cells) or harmful side effects.
• Eye-Safe: Meets ANSI Z80.36 and IEC 62471 standards for light exposure safety.

Is Valeda Right for You?

• Early to intermediate Dry AMD
• Experiencing central vision distortion
• Prefer a non-surgical option
• Have stable general eye health

Learn about Valeda, the first and only FDA-cleared light-based treatment for Dry Age-Related Macular Degeneration (AMD). This brochure explains symptoms, how the therapy works, and who may benefit. Early diagnosis and treatment with Valeda can help preserve vision and improve retinal health.

Who is Eligible for Valeda?

Valeda is designed for patients with:

• Best Corrected Visual Acuity (BCVA): Between 20/32 and 20/70.
• Dry AMD Characteristics: 
  • Presence of medium or large drusen. (see picture below for what drusen looks like under the “Visual Evidence” section below)
  • Non-central geographic atrophy.
• No Neovascular Maculopathy: Patients with uncontrolled wet AMD or center-involving GA are generally not good candidates for treatment. Each case is unique, and we recommend you see us for a thorough evaluation and our recommendations.
• Other “off-label” Benefits: non-cental wet AMD, well-controlled early wet AMD, diabetic macular edema, select cases of graphic atrophy (GA), mixed dry and wet AMD, central serous chorioretinopathy. These possible treatments are evaluated individually, followed by a discussion with each patient. See example of central serous chorioretinopathy under the second “Visual Evidence” heading below.

Find out if you are a candidate today!

LumiThera Valeda: Clinical Results

Valeda has shown up to 7-letter improvements in visual acuity in clinical trials. Over 70% of treated eyes experienced vision improvement or stabilization, with zero serious adverse events.

Visual Evidence

Representative OCT images show a significant reduction in macular drusen volume after PBM treatment, with no loss of photoreceptor or retinal pigment epithelium.

What to Expect During Treatment

Don’t wait to protect your vision.